Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) announced its earnings results on Tuesday. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08), Zacks reports.
Checkpoint Therapeutics Price Performance
NASDAQ:CKPT opened at $3.62 on Thursday. The stock has a market cap of $162.97 million, a P/E ratio of -1.97 and a beta of 1.23. The company has a fifty day moving average price of $2.76 and a 200 day moving average price of $2.32. Checkpoint Therapeutics has a one year low of $1.36 and a one year high of $3.97.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, September 16th.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Top 3 R&D-Driven Stocks Showing Strong Profit and Momentum
- Best Stocks Under $10.00
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- Roth IRA Calculator: Calculate Your Potential Returns
- Tariff Troubles: 3 Stocks Planning Higher Prices
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
